J2 Capital Management Inc bought a new position in GSK plc (NYSE:GSK - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 17,613 shares of the pharmaceutical company's stock, valued at approximately $596,000.
Several other institutional investors also recently modified their holdings of GSK. Eastern Bank bought a new stake in GSK during the third quarter worth $26,000. ST Germain D J Co. Inc. increased its position in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. Sunbelt Securities Inc. raised its stake in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company's stock worth $29,000 after purchasing an additional 302 shares during the period. Concord Wealth Partners raised its stake in shares of GSK by 231.8% during the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company's stock worth $32,000 after purchasing an additional 547 shares during the period. Finally, Fortitude Family Office LLC purchased a new position in shares of GSK in the 3rd quarter worth about $42,000. 15.74% of the stock is owned by institutional investors.
NYSE:GSK opened at $33.46 on Friday. The business's fifty day moving average is $34.02 and its 200 day moving average is $37.98. The firm has a market cap of $69.34 billion, a price-to-earnings ratio of 21.72, a PEG ratio of 1.44 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92.
The business also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were given a dividend of $0.3928 per share. The ex-dividend date of this dividend was Friday, November 15th. This is a boost from GSK's previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.70%. GSK's dividend payout ratio is currently 96.10%.
GSK has been the topic of several research reports. StockNews.com raised shares of GSK from a "buy" rating to a "strong-buy" rating in a research report on Monday, January 13th. Jefferies Financial Group cut shares of GSK from a "buy" rating to a "hold" rating and lowered their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered GSK from a "buy" rating to a "hold" rating in a report on Friday, November 15th. Finally, Guggenheim cut GSK from a "buy" rating to a "neutral" rating in a research report on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company's stock. According to MarketBeat, GSK presently has a consensus rating of "Moderate Buy" and an average target price of $43.25.
Read Our Latest Research Report on GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.